Chime Biologics and Magic Mirror Biotech Enter Strategic Partnership to Advance AI-Enabled Intelligent Manufacturing Across the Biologics Lifecycle

  • Chime Biologics and Magic Mirror Biotech have entered into a strategic partnership to integrate Magic Mirror’s capabilities in AI + mechanistic modeling, its Optimizer platform, digital twins, and intelligent process optimization into the Chime AI Platform.
  • The two companies will jointly advance the application of AI from research into process development and manufacturing, building a full-lifecycle AI solution spanning biologics R&D, CMC, and commercial manufacturing.
  • Chime Biologics’ Megafactory will serve as a key application environment for the Chime AI Platform, where the companies will explore AI-driven process optimization, manufacturing, and continuous improvement with the ambition of building and operating a world-leading intelligent biologics manufacturing facility.

WUHAN, China | September 2026 — Chime Biologics, a global biologics CDMO dedicated to enabling partners’ success, and Magic Mirror Biotech have formally entered into a strategic partnership. The two companies will collaborate closely on applying artificial intelligence to biologics R&D and manufacturing, further enhancing the Chime AI Platform through technology integration and extending AI capabilities from research into process development and manufacturing.

Chime Biologics has long viewed AI as an important force for transforming biomanufacturing and has been continuously developing the Chime AI Platform to embed AI capabilities across key stages from research and development through manufacturing. The strategic partnership with Magic Mirror will further strengthen the Chime AI Platform in process development and intelligent manufacturing, enabling AI to play a deeper role in biologics manufacturing.

Dr. Jimmy Wei, Board Director and Chief Executive Officer of Chime Biologics, said:
“Artificial intelligence is evolving from a tool for improving R&D efficiency into an important force reshaping biologics R&D and manufacturing. Through the Chime AI Platform, we aim to connect AI capabilities across research, process development, and manufacturing, and ultimately scale their application in real-world industrial settings. Our partnership with Magic Mirror will further strengthen our capabilities in process development and intelligent manufacturing. Looking ahead, we also expect the Megafactory to serve as an important application environment where AI can truly enter the production line and drive biomanufacturing toward a more intelligent future.”

Dr. Kenneth Kang, Founder and Chief Executive Officer of Magic Mirror Biotech, said:
“The value of AI combined with mechanistic modeling lies not only in improving the efficiency of individual process steps, but also in connecting scientific principles, process expertise, and real-world manufacturing data to create intelligent systems that can continuously learn and optimize. We look forward to working closely with Chime Biologics to integrate Magic Mirror’s capabilities in digital twins and intelligent process optimization with the Chime AI Platform’s full-lifecycle approach, and to jointly explore new opportunities for AI across biologics R&D, process development, and manufacturing.”

AI + Mechanistic Modeling and the Magic Mirror Optimizer Platform: Bringing AI into Biomanufacturing

Magic Mirror Biotech focuses on the intelligent transformation of biologics manufacturing processes. Its core technologies are based on AI + mechanistic modeling and the Optimizer platform, with next-generation digital twin capabilities enabling analysis, prediction, optimization, and intelligent control of biologics manufacturing processes. Its technologies cover multiple critical stages of the CMC lifecycle, from process design and development to process qualification and continued process verification.

In practical applications, Magic Mirror combines AI/ML with mechanistic models and continuously trains and optimizes these models using historical process development data and manufacturing data. This creates a closed loop of “virtual experiments, prediction of optimal conditions, scale-up verification, manufacturing data feedback, and continuous model iteration,” while covering critical unit operations including upstream cell culture and downstream purification.

Magic Mirror’s product portfolio supports progressive levels of intelligentization, ranging from an offline process assistant to real-time process guidance, collaborative production control, autonomous control of individual production units, and ultimately site-wide autonomous production. This technology approach has already been validated in actual commercial manufacturing.

Through this strategic partnership, Magic Mirror’s AI capabilities will be integrated into the Chime AI Platform, extending Chime Biologics’ AI capabilities from research and data analytics into process development, manufacturing optimization, and continued process verification, and bringing AI further into the core of biomanufacturing.

Megafactory: A Real-World Application Environment for the Chime AI Platform

The ultimate value of AI must be validated and amplified in real-world industrial applications. Chime Biologics’ planned Megafactory will not only be a large-scale biologics manufacturing facility designed for the future, but also an important application environment for the Chime AI Platform.

The Megafactory will further connect research, process development, and manufacturing, bringing virtual experimentation, process prediction and optimization, manufacturing data analytics, and continued process verification into a more integrated closed loop. By combining Magic Mirror’s digital twin and intelligent process optimization capabilities, Chime Biologics aims to progressively enable real-time process sensing, intelligent analysis, decision support, and continuous optimization, bringing AI from the digital environment into the production line.

About Magic Mirror Biotech

Magic Mirror Biotech, headquartered in Suzhou Industrial Park, was co-founded by leading industrialization experts in biopharmaceuticals and professors from renowned universities. The company focuses on digitalization and intelligent transformation in biopharmaceuticals, leveraging its core technology of “Next-Generation Digital Twins (AI + Mechanistic Modeling)” to help the industry improve quality and efficiency and unlock greater value. Magic Mirror provides full-value-chain capabilities and growth momentum for biopharmaceutical companies pursuing high-quality development.

For more information, please visit: www.magicmirrorbiotech.com.

About Chime Biologics

Chime Biologics is a leading global CDMO, focused on ensuring our customers' success in delivering innovative biologics as well as biosimilars to patients across the world. Chime Biologics can support customers end to end, from pre-clinical support and cell line development through to clinical and commercial manufacturing of drug substance and drug product. Employing our state-of-the-art capabilities in our Europe Innovation Hub (Basel, CH), China Innovation Hub (Shanghai, CN), Development & Manufacturing Campus (Wuhan, CN) and proven success in supporting our clients with their clinical and commercial authorizations across the globe, Chime Biologics is a true end-to-end solution provider for the biologics industry and we share a common goal to make cutting-edge biologics affordable and accessible to patients worldwide, fulfilling our commitment to improving human health globally.

For more information, please visit www.chimebiologics.com.